ResearchRadar
ResearchRadar
How it worksSourcesUse casesWeekly radar
ENESCADEZHJAHISign inStart free
LIVE TEMPLATE · READ ONLYNo account required

Cancer genomics

Cancer genomics, biomarkers, precision oncology and translational evidence.

Search query“cancer genomics precision oncology mutations biomarkers”
Last 7 days6 sources15 findings

Sources in this radar

Select one or more sources to filter the results.

15 results
P
PaperPubMed·Oct 1, 2026

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission.

Published in The Lancet. Oncology. Open the PubMed record for the abstract and publication details.

DOI
10.1016/S1470-2045(26)00302-5 ↗
Authors
Casolino R, Mateo J, de Vries EGE, Johns A, Courtot M, Lawlor RT, Perdomo S, Gray SW, Perez-Lopez R, Turnbull C, Torrents D, Vokinger KN, et al.
Journal / venue
The Lancet. Oncology
Publication type
Journal Article
Status
Published
Cancer genomics97% relevantRead original ↗
EP
PaperEurope PMC·Oct 1, 2026

Economic value and clinical role of minimally invasive, biopsy-based diagnostics in non-small cell lung cancer.

Background Precision oncology requires diagnostic sampling that delivers molecularly actionable material quickly and safely. In non-small cell lung cancer (NSCLC), core-needle biopsy (CNB) remains common. Yet fine-needle aspiration (FNA) has re-emerged with rapid on-site evaluation (ROSE), optimized cell blocks, and next-generation sequencing. The objective of this study was to compare the economic costs of FNA vers…

DOI
10.1002/cncy.70152 ↗
Authors
Guo J, Franzén B, Lewensohn R, Hysek M, Jönsson L.
Journal / venue
Not supplied
Publication type
Journal article
Status
Published
Cancer genomics89% relevantRead original ↗
NM
PaperNature Medicine·Sep 30, 2026

Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial

Nature Medicine, Published online: 30 September 2026; doi:10.1038/s41591-026-04705-y In the randomized phase 2b VIRAGE trial, patients with treatment-naive metastatic pancreatic cancer received the hyaluronidase-expressing oncolytic adenovirus zabilugene almadenorepvec (VCN-01) intravenously with gemcitabine and nab-paclitaxel (GnP) or GnP alone, showing that VCN-01 plus GnP led to prolonged overall survival.

DOI
10.1038/s41591-026-04705-y ↗
Authors
Rocio Garcia-Carbonero
Journal / venue
Nature Medicine
Publication type
Journal article
Status
Published
Cancer genomics89% relevantRead original ↗
EP
PaperEurope PMC·Oct 1, 2026

Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.

Distinguishing early melanoma from borderline, atypical, or biologically intermediate melanocytic lesions remains one of the most consequential and urgent diagnostic challenges in dermato-oncology, since melanoma causes nearly 95% of skin cancer deaths. This narrative review establishes the biological relevance and evaluates the clinical maturity of mass spectrometry-based proteomics, with particular emphasis on spa…

DOI
10.1111/ijd.70665 ↗
Authors
Szadai L, Gil J, Marko-Varga G.
Journal / venue
Not supplied
Publication type
Journal article
Status
Published
Cancer genomics87% relevantRead original ↗
EP
PaperEurope PMC·Oct 1, 2026

A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response.

Although genetic sequencing is routine in cancer care, translating a tumor's complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is pretrained on a large corpus of genomic alterations across more than 30,000 tumors, integrated with extensive molecular knowledge. The resulting projection reveals a tumor's altered molecular pathways, facilitating model interpreta…

DOI
10.1158/2159-8290.cd-25-1735 ↗
Authors
Kong J, Lee I, Boecher D, Singhal A, Kelly MR, Moon J, Ahn CH, Ock CY, Pratt D, Kumar T, Sears TJ, Laub D, Wright S, Wall P, Carter H, Wang Z, Ideker T.
Journal / venue
Not supplied
Publication type
Journal article
Status
Published
Cancer genomics87% relevantRead original ↗
NM
PaperNature Medicine·Oct 1, 2026

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Nature Medicine, Published online: 01 October 2026; doi:10.1038/s41591-026-04677-z An updated pooled analysis of 3-year and 5-year survival and other outcome data of 1,038 patients with melanoma treated with neoadjuvant immune checkpoint inhibitors (ICIs), BRAF and MEK inhibitors (BRAF/MEKis), or a combination of ICIs and targeted therapies shows that ICI as monotherapy or in ICI combinations are superior to BRAF/ME…

DOI
10.1038/s41591-026-04677-z ↗
Authors
Georgina V. Long
Journal / venue
Nature Medicine
Publication type
Journal article
Status
Published
Cancer genomics87% relevantRead original ↗
NM
PaperNature Medicine·Sep 29, 2026

A synthetic lethal drug for microsatellite instability cancers

Nature Medicine, Published online: 29 September 2026; doi:10.1038/s41591-026-04693-z In a phase 1 trial, inhibition of the Werner syndrome helicase (WRN) enzyme exploits a new synthetic lethal vulnerability in cancers with microsatellite instability, offering a new way to target these tumors beyond immune checkpoint inhibition.

DOI
10.1038/s41591-026-04693-z ↗
Authors
Jia Liu
Journal / venue
Nature Medicine
Publication type
Journal article
Status
Published
Cancer genomics87% relevantRead original ↗
NM
PaperNature Medicine·Oct 1, 2026

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial

Nature Medicine, Published online: 01 October 2026; doi:10.1038/s41591-026-04674-2 A randomized trial in individuals with type 2 diabetes probed the kidney-protective mechanisms of semaglutide using a range of techniques, including histology, multiparametric MRI and transcriptomics.

DOI
10.1038/s41591-026-04674-2 ↗
Authors
Katherine R. Tuttle
Journal / venue
Nature Medicine
Publication type
Journal article
Status
Published
Cancer genomics85% relevantRead original ↗
P
PaperPubMed·Oct 1, 2026

Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).

Published in Oncology reports. Open the PubMed record for the abstract and publication details.

DOI
10.3892/or.2026.9188 ↗
Authors
Wang L, Feng Y, Liu Q
Journal / venue
Oncology reports
Publication type
Journal Article
Status
Published
Cancer genomics83% relevantRead original ↗
NG
PaperNature Genetics·Oct 1, 2026

Reactivation of the embryonic ζ-globin gene ameliorates severe forms of α-thalassemia

Nature Genetics, Published online: 01 October 2026; doi:10.1038/s41588-026-02770-0 Liu et al. identify cis-regulatory elements that silence the embryonic ζ-globin gene in definitive erythroid cells. Gene-editing strategies reactivate ζ-globin expression to therapeutically relevant levels in mouse and human disease models.

DOI
10.1038/s41588-026-02770-0 ↗
Authors
Siyu Liu
Journal / venue
Nature Genetics
Publication type
Journal article
Status
Published
Cancer genomics81% relevantRead original ↗
PG
PaperPLOS Genetics·Sep 30, 2026

The prevalence of protein misfolding as a mechanism for hereditary deafness

Open the original publication to read the full article.

DOI
Not supplied
Authors
Sarah Frieda Becker, Marie-Charlotte Morin, Julien Lambert, Shashi Kumar Suman, Francesco Nicola Carelli, Alex Appert, Stéphane Roth, Sarah Hoff-Yoessle, Jessica D. Medina-Sanchez, Manuela Portoso, Julie Ahringer, Sophie Jarriault
Journal / venue
Not supplied
Publication type
Journal article
Status
Published
Cancer genomics81% relevantRead original ↗
NG
PaperNature Genetics·Sep 30, 2026

Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance

Nature Genetics, Published online: 30 September 2026; doi:10.1038/s41588-026-02768-8 KRAS-mutant lung cancers frequently develop resistance to targeted inhibition. This study demonstrates that lineage plasticity shapes oncogene dependence during response and resistance to KRAS inhibition, establishing new models of histologic transformation.

DOI
10.1038/s41588-026-02768-8 ↗
Authors
Nicolas Mathey-Andrews
Journal / venue
Nature Genetics
Publication type
Journal article
Status
Published
Cancer genomics81% relevantRead original ↗
P
PaperPubMed·Oct 1, 2026

Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies.

Published in Bulletin du cancer. Open the PubMed record for the abstract and publication details.

DOI
10.1016/j.bulcan.2026.04.016 ↗
Authors
Karikalan B, Linn YH, Mok SL
Journal / venue
Bulletin du cancer
Publication type
Journal Article
Status
Published
Cancer genomics79% relevantRead original ↗
EP
PaperEurope PMC·Oct 1, 2026

CCNE1: A Cell Cycle Regulator That Influences Tumor Progression.

Cyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin-dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S-phase entry. In a broad spectrum of human malignancies-including breast, ovarian, gastric, and non-small cell lung cancers-amplification or overexpression of CCNE1 disrupts the orderly regulation o…

DOI
10.1002/cam4.72336 ↗
Authors
Yan L, Liu S, Li Y, He Q, Long C, Tang N, Zhou Y.
Journal / venue
Not supplied
Publication type
Journal article
Status
Published
Cancer genomics79% relevantRead original ↗
NG
PaperNature Genetics·Sep 30, 2026

Single-cell profiling and genetic regulation of alternative polyadenylation in the human brain

Nature Genetics, Published online: 30 September 2026; doi:10.1038/s41588-026-02758-w This study provides a single-cell atlas of 3′ untranslated region regulation in the human brain, pointing to molecular mechanisms for genetic variants contributing to Alzheimer’s disease, Parkinson’s disease and other brain disorders beyond gene expression.

DOI
10.1038/s41588-026-02758-w ↗
Authors
Jiuhong Nan
Journal / venue
Nature Genetics
Publication type
Journal article
Status
Published
Cancer genomics79% relevantRead original ↗
Powered by ResearchRadarResults collected: Oct 2, 2026, 3:30 AM UTCRefreshes approximately every 15 minutes
A real radar, without the commitment.Open every original publication and explore the ranked results. An account is only needed to save findings, change the setup or receive the daily brief.

Want to make this radar yours?

Create a free account with this topic, query, freshness window and source set ready to edit.

Try another template